The oncobiome; what, so what, now what?

Area of Science:

• Oncology
• Microbiology
• Immunology

Background:

• Microbial communities in the gut and at tumor sites influence cancer development and patient outcomes.
• The tumor microenvironment (TME) is shaped by local and systemic microbiota, affecting cancer progression.
• Microbiota interactions with immune cells modulate inflammation and immune surveillance, impacting cancer risk.

Purpose of the Study:

• To explore the complex roles of microbiomes in cancer, focusing on TME modulation, immune activation, and treatment efficacy.
• To highlight the diagnostic and therapeutic potential of microbial communities in advancing precision oncology.

Main Methods:

• Review of current literature on the interplay between microbiomes and cancer.
• Analysis of mechanisms by which bacteria influence cancer therapies, including drug metabolism and TME modification.
• Examination of microbial signatures for cancer diagnosis and prediction of treatment response.

Main Results:

• Gut and intratumoral microbiota can alter cancer drug metabolism, affecting therapeutic efficacy.
• Specific bacterial species are associated with improved responses to immunotherapy and other cancer treatments.
• Distinct microbial signatures differentiate cancer patients from healthy individuals, indicating diagnostic potential.

Conclusions:

• The microbiome plays a critical role in cancer initiation, progression, immune response, and therapeutic outcomes.
• Leveraging microbial biomarkers and interventions holds promise for optimizing cancer diagnosis and treatment strategies.
• Targeting the microbiome represents a promising frontier for advancing precision oncology and improving patient care.